The article “Immunomonitoring of human responses to the rVSV-ZEBOV Ebola Vaccine” was published in Current Opinion in Virology journal with the acknowledgment of the VSV-EBOVAC Consortium.
It is reported that the rVSV-ZEBOV Vaccine is currently the only one vaccine with demostrated clinical efficacy in a ring-vaccination clinical trial. This vaccine has shown to be reactogenic but immunogenic and safe in several Phase I clinical studies. However, its mechanisms of protection are unknown and available immunogenicity data are mostly limited to classical serological analysis. Cutting-edge technologies, including transcriptomic and metabolomic analyses, are currently being applied to perform integrative analyses with standard serology and clinical data to comprehnsively profile the rVSV-ZEBOV immune signature.
Full text article.